Other key drugs like Naglazyme and Vimizim are also ... BioMarin’s top-line growth is expected to have been partially offset by lower Kuvan sales, which have been suffering from generic erosion.

The company attributed some of the top-line weakness to lower sales of Naglazyme due to the timing of certain government orders and Kuvan ... development of four drug candidates: BMN 331, BMN ...

Drug treatment is an option for some patients, with BioMarin's enzyme-based therapies Kuvan (sapropterin) or Palynziq (pegvaliase) both approved to reduce levels of the amino acid, although they ...

There are a couple of drug treatments available, namely BioMarin’s enzyme-based therapies Kuvan (sapropterin) or Palynziq (pegvaliase), which are both approved to reduce levels of phe.